{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:06:26Z","timestamp":1792821986029,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40264-016-0431-z","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T11:23:10Z","timestamp":1465471390000},"page":"755-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis"],"prefix":"10.1007","volume":"39","author":[{"given":"Megan E. B.","family":"Clowse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Xibill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Proulx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Marren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"431_CR1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D Heijde van der","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum"},{"key":"431_CR2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet"},{"key":"431_CR3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"431_CR4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u201361.","journal-title":"Ann Intern Med"},{"key":"431_CR5","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med"},{"key":"431_CR6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med"},{"key":"431_CR7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase Inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41:837\u201352.","journal-title":"J Rheumatol"},{"key":"431_CR8","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","volume":"172","author":"R Bissonnette","year":"2015","unstructured":"Bissonnette R, Iversen L, Sofen H, Griffiths CEM, Foley P, Romiti R, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172:1395\u2013406.","journal-title":"Br J Dermatol"},{"key":"431_CR9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949\u201361.","journal-title":"Br J Dermatol"},{"key":"431_CR10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552\u201361.","journal-title":"Lancet"},{"key":"431_CR11","unstructured":"Pfizer Inc. Xeljanz prescribing information. 2014. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959 . Accessed 26 Mar 2016."},{"key":"431_CR12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis."},{"key":"431_CR13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/bdra.23003","volume":"94","author":"SC Hyoun","year":"2012","unstructured":"Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94:187\u2013207.","journal-title":"Birth Defects Res A Clin Mol Teratol."},{"key":"431_CR14","unstructured":"Organization of Teratology Information Specialists (OTIS) registry. 2016. http:\/\/parthenonmanagementgroup.com\/portfolio\/organization-of-teratology-information-specialists-otis\/ . Accessed 23 Mar 2016."},{"key":"431_CR15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1148\/radiology.181.1.1887021","volume":"181","author":"FP Hadlock","year":"1991","unstructured":"Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology. 1991;181:129\u201333.","journal-title":"Radiology"},{"key":"431_CR16","unstructured":"American College of Obstetricians and Gynecologists. Miscarriage and molar pregnancy. 2011. http:\/\/www.lexingtonobgyn.com\/webdocuments\/acog\/early-pregnancy-loss.pdf ."},{"key":"431_CR17","first-page":"1","volume":"57","author":"L Rynn","year":"2008","unstructured":"Rynn L, Cragan J, Correa A. Update on overall prevalence of major birth defects\u2013Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008;57:1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"431_CR18","unstructured":"Royal College of Obstetricians and Gynaecologists. NICE Clinical Guidelines: Ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. 2012. https:\/\/www.nice.org.uk\/guidance\/cg154 . Accessed 5 May 2016."},{"key":"431_CR19","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","volume":"320","author":"AM Nybo Andersen","year":"2000","unstructured":"Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320:1708\u201312.","journal-title":"BMJ."},{"key":"431_CR20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0015-0282(02)04694-0","volume":"79","author":"X Wang","year":"2003","unstructured":"Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril. 2003;79:577\u201384.","journal-title":"Fertil Steril"},{"key":"431_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1590\/S0100-72032010000300002","volume":"32","author":"JG Cecatti","year":"2010","unstructured":"Cecatti JG, Guerra GV, Sousa MH, Menezes GM. Abortion in Brazil: a demographic approach. Rev Bras Ginecol Obstet. 2010;32:105\u201311.","journal-title":"Rev Bras Ginecol Obstet."},{"key":"431_CR22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2796.2010.02239.x","volume":"268","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Larsson H, Pedersen L, Granath F, Askling J, Kieler H, et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med. 2010;268:329\u201337.","journal-title":"J Intern Med"},{"key":"431_CR23","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3899\/jrheum.140583","volume":"42","author":"B Bharti","year":"2015","unstructured":"Bharti B, Lee SJ, Lindsay SP, Wingard DL, Jones KL, Lemus H, et al. Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the Organization of Teratology Information Specialists Autoimmune Diseases in Pregnancy Project. J Rheumatol. 2015;42:1376\u201382.","journal-title":"J Rheumatol"},{"key":"431_CR24","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","volume":"60","author":"YA Man de","year":"2009","unstructured":"de Man YA, Hazes JM, van der Heide H, Willemsen SP, de Groot CJ, Steegers EA, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 2009;60:3196\u2013206.","journal-title":"Arthritis Rheum"},{"key":"431_CR25","first-page":"9","volume":"31","author":"ES Langen","year":"2014","unstructured":"Langen ES, Chakravarty EF, Liaquat M, El-Sayed YY, Druzin ML. High rate of preterm birth in pregnancies complicated by rheumatoid arthritis. Am J Perinatol. 2014;31:9\u201314.","journal-title":"Am J Perinatol"},{"key":"431_CR26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1468-3083.2010.03917.x","volume":"25","author":"E Cohen-Barak","year":"2011","unstructured":"Cohen-Barak E, Nachum Z, Rozenman D, Ziv M. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2011;25:1041\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"431_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/jid.2011.271","volume":"132","author":"XT Lima","year":"2012","unstructured":"Lima XT, Janakiraman V, Hughes MD, Kimball AB. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol. 2012;132:85\u201391.","journal-title":"J Invest Dermatol."},{"key":"431_CR28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.38368","volume":"66","author":"C Weber-Schoendorfer","year":"2014","unstructured":"Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101\u201310.","journal-title":"Arthritis Rheumatol."},{"key":"431_CR29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0002-9343(90)90522-F","volume":"88","author":"RD Kozlowski","year":"1990","unstructured":"Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990;88:589\u201392.","journal-title":"Am J Med"},{"key":"431_CR30","first-page":"599","volume":"99","author":"C Nguyen","year":"2002","unstructured":"Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol. 2002;99:599\u2013602.","journal-title":"Obstet Gynecol"},{"key":"431_CR31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/art.24462","volume":"61","author":"E Vinet","year":"2009","unstructured":"Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum. 2009;61:587\u201392.","journal-title":"Arthritis Rheum"},{"key":"431_CR32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1759720X14551568","volume":"6","author":"ML Krause","year":"2014","unstructured":"Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis. 2014;6:169\u201384.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"431_CR33","first-page":"27","volume":"23","author":"L Mervic","year":"2014","unstructured":"Mervic L. Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. Acta Dermatovenerol Alp Pannonica Adriat. 2014;23:27\u201331.","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat."},{"key":"431_CR34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ad.2013.06.005","volume":"105","author":"V Ruiz","year":"2014","unstructured":"Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr. 2014;105:813\u201321.","journal-title":"Actas Dermosifiliogr."},{"key":"431_CR35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bcp.12642","volume":"80","author":"C Weber-Schoendorfer","year":"2015","unstructured":"Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727\u201339.","journal-title":"Br J Clin Pharmacol"},{"key":"431_CR36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.gtc.2014.05.005","volume":"43","author":"S Horst","year":"2014","unstructured":"Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am. 2014;43:495\u2013508.","journal-title":"Gastroenterol Clin North Am"},{"key":"431_CR37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2010.140822","volume":"70","author":"SM Verstappen","year":"2011","unstructured":"Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823\u20136.","journal-title":"Ann Rheum Dis"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0431-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-016-0431-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0431-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T12:01:58Z","timestamp":1498305718000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-016-0431-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1007\/s40264-016-0431-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}